Compare BIIB & ZM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BIIB | ZM |
|---|---|---|
| Founded | 1978 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Computer Software: Programming Data Processing |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 27.1B | 21.8B |
| IPO Year | 1996 | 2019 |
| Metric | BIIB | ZM |
|---|---|---|
| Price | $178.01 | $87.51 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 27 | 22 |
| Target Price | ★ $199.46 | $94.14 |
| AVG Volume (30 Days) | 1.1M | ★ 3.6M |
| Earning Date | 04-29-2026 | 05-20-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 92.52 |
| EPS | ★ 8.79 | 6.18 |
| Revenue | ★ $9,890,600,000.00 | $4,868,769,000.00 |
| Revenue This Year | N/A | $7.30 |
| Revenue Next Year | N/A | $3.96 |
| P/E Ratio | $20.54 | ★ $14.40 |
| Revenue Growth | 2.22 | ★ 4.36 |
| 52 Week Low | $115.28 | $69.15 |
| 52 Week High | $202.41 | $97.58 |
| Indicator | BIIB | ZM |
|---|---|---|
| Relative Strength Index (RSI) | 45.57 | 61.51 |
| Support Level | $170.52 | $86.74 |
| Resistance Level | $188.76 | $91.12 |
| Average True Range (ATR) | 5.78 | 3.30 |
| MACD | -0.09 | 0.93 |
| Stochastic Oscillator | 38.76 | 76.71 |
Biogen is an established biopharmaceutical company focused on treatments for neurodegenerative and rare diseases. Its declining multiple sclerosis franchise is its largest revenue generator and contributed 40% of total revenue in 2025. Biogen also generates significant revenue from its CD20 collaboration agreements with Roche (19% of total in 2025), which includes oncology drugs Rituxan and Gazyva and multiple sclerosis drug Ocrevus. Biogen's newer franchises include Spinraza (spinal muscular atrophy, with partner Ionis), Leqembi (Alzheimer's disease, collabroation revenue from its partner Eisai), Skyclarys (Friedreich's ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (amyotrophic lateral sclerosis, Ionis).
Zoom Communications provides a video-first communications platform that connects people through frictionless video, voice, chat, and content sharing. The company's cloud-native platform enables video experiences and connects users across various devices and locations in a single meeting. Zoom has launched a variety of communications-related solutions, including Zoom Phone and Zoom Contact Center. The firm was founded in 2011 and serves companies of all sizes from all industries around the world.